Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sanofi Consumer Healthcare India Debt-to-EBITDA?
Sanofi Consumer Healthcare IndiaNSE:SANOFICONR +1.08%22 Debt-to-EBITDA is 0.05 as of Jun. 2026, which is 38% below its 10-year median of 0.08. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 675 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks better than 90.37% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sanofi Consumer Healthcare India's Debt-to-EBITDA or its related term are showing as below:
NSE:SANOFICONR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06 Med: 0.08 Max: 0.08
Current: 0.06
During the past 3 years, the highest Debt-to-EBITDA Ratio of Sanofi Consumer Healthcare India was 0.08. The lowest was 0.06. And the median was 0.08.
NSE:SANOFICONR's Debt-to-EBITDA is ranked better than 90.37% of 675
companies
in the Drug Manufacturers industry
Industry Median: 1.62
vs NSE:SANOFICONR: 0.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sanofi Consumer Healthcare India Debt-to-EBITDA Related Terms
Sanofi Consumer Healthcare India Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India Debt-to-EBITDA Chart
NSE:SANOFICONR vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a Debt-to-EBITDA of 0.05 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sanofi Consumer Healthcare India. This is 38% below median its historical median of 0.08. Over the past decade, Sanofi Consumer Healthcare India's Debt-to-EBITDA has ranged from 0.06 to 0.08. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #65 out of 675 companies in the Drug Manufacturers industry, placing it in the top 9.6%.
Is Sanofi Consumer Healthcare India's Debt-to-EBITDA too high?
Sanofi Consumer Healthcare India's current Debt-to-EBITDA of 0.05 is 38% below median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.08. The Drug Manufacturers industry median Debt-to-EBITDA is 1.62. Sanofi Consumer Healthcare India's value of 0.05 is 96.9% below this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #65 out of 675 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #65 out of 675 companies for Debt-to-EBITDA. This places Sanofi Consumer Healthcare India in the top 10% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.62. Sanofi Consumer Healthcare India's value of 0.05 is 96.9% below this benchmark. Historically, Sanofi Consumer Healthcare India's own Debt-to-EBITDA has ranged from 0.06 to 0.08 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 1.62, Sanofi Consumer Healthcare India has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.62, based on 675 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current Debt-to-EBITDA of 0.05 is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sanofi Consumer Healthcare India. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current Debt-to-EBITDA is 0.05, which is 38% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current Debt-to-EBITDA of 0.05. The current Debt-to-EBITDA is 0.05, which is 38% below median its 10-year median of 0.08 and 96.9% below the Drug Manufacturers industry median of 1.62. Sanofi Consumer Healthcare India's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current Debt-to-EBITDA is 0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
22GF Score
Get the complete analysis for NSE:SANOFICONR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
